Tag:

Lamberto Andreotti

Latest Headlines

Latest Headlines

Bristol-Myers chief's last 'paycheck' as CEO is a doozy at $27M

Bristol-Myers Squibb CEO Lamberto Andreotti has had a nice run at the drugmaker, paywise. And as he prepares to move upstairs to the chairman's office--and eventually out the door--he's going out with a bang. Apparently, a $27 million bang.

Bristol-Myers says COO Caforio to take over as CEO

Chief Operating Officer Giovanni Caforio will take over the top exec job at Bristol-Myers Squibb on May 5, when 64-year-old Lamberto Andreotti steps down from the role he has held for 5 years and takes over instead as executive chairman of the board.

15 Highest-Paid Biopharma CEOs of 2013

Long dominated by global behemoths like Johnson & Johnson and Pfizer, this executive-pay ranking now includes almost as many biotechs as pharma companies.

Bristol-Myers impresses with trimmed-down costs, pumped-up sales

Bristol-Myers Squibb's got some pumped-up sales to go along with its slimmed-down focus. In the fourth quarter, revenue increases and decreased costs helped the company beat Wall Street's earnings estimates on the way to zeroing in on its new-look pharma model.

Despite sales slide, Bristol-Myers CEO nabs 15% raise to $17.2M

Bristol-Myers Squibb CEO Lamberto Andreotti got a 15% raise last year. And that's on top of a 26% increase the year before. Andreotti's 2012 compensation package amounted to $17.2 million, up from $11.8 million two years ago.

New BMS drugs will fill yawning Plavix gap, CEO says

Bristol-Myers Squibb's ($BMY) fourth-quarter sales are about as pure an example of generic erosion as we're likely to get. Was 2012 truly a "transition year" for Bristol-Myers, as CEO Lamberto Andreotti insists?

Bristol-Myers to slash 480 sales-related jobs in NJ

Bristol-Myers Squibb ($BMY) is following up its lackluster third-quarter results with almost 480 layoffs. As Pharmalot reports, the company notified the New Jersey government that it would scale back in Plainsboro, which means the cuts will hit its sales operations.

BMS results crater on 96% drop in Plavix sales

Bristol-Myers Squibb's ($BMY) third quarter continues the generics-are-poison trend. The company saw sales drop by 30%--yes, 30%--as copycats siphoned off sales from its big-selling blood-pressure drugs Avapro and Avalide, and its even bigger clot-fighting treatment Plavix.

Does Bristol's tarnished rep put CEO among the year's worst?

Poor Lamberto Andreotti. Just a year ago, the Bristol-Myers Squibb ($BMY) CEO was accepting bouquets for his company's better-than-the-rest reputation in Big Pharma. Now, he's nominated as the year's worst CEO.

Gilead preps late-stage sprint on blockbuster hep C studies

It looks as if Gilead can't be shamed into a late-stage hepatitis C collaboration with Bristol-Myers Squibb after all.